Controlled Trial of Nimodipine in Acute Ischemic Stroke


Phase N/A Results

Trial Description

To determine whether treatment with a calcium-channel blocker would improve survival and neurologic outcome in acute ischemic stroke.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Prospective, double-blind, randomized, placebo-controlled trial involving 186 patients at 4 regional hospitals.

Patient Involvement

Patients were randomized to receive nimodipine (30 mg every six hours) or placebo for 4 weeks.


Type Measure Time Frame Safety Issue
Primary Matthew Scale of neurologic deficit at 28 days and death during treatment period and 6-month follow-up.


Bayer AG